Tag Archives: first-in-class

Evotec Achieves Major Milestones in Molecular Glue Degrader Collaboration with Bristol Myers Squibb, Unlocks $75 Million in Payments

(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release